What is pemphigus? Pemphigus is a type of disease where the body’s immune system attacks healthy cells in the top layer of skin (epidermis). It causes blisters on the skin and in the mouth, nose, throat, eyes, and genitals. Some forms of pemphigus can cause death if not treated.
What are growth plate injuries? The growth plate is the area of tissue near the ends of long bones in children and teens that determines what length and shape the bone will be once it is done growing. Each long bone— the thigh bone, the bones in the forearm, and the bones in the hands and fingers—has at least two growth plates, one at each end. Once your child has finished growing, the growth plates close and are replaced by solid bone. The growth plates are weak areas of your child’s growing skeleton, making it easier to injure them. Injuries
What is tendinitis? Tendinitis is swelling and pain in a tendon, which is tissue that connects muscles to bones. It is a common condition, usually caused by repeated injuries to a tendon.
What are arthritis and rheumatic diseases? The term arthritis is often used to refer to any disorder that affects the joints. There are more than 100 rheumatic diseases. Rheumatic diseases usually affect joints, tendons, ligaments, bones, and muscles. Some rheumatic diseases can also affect the organs.
What is ankylosing spondylitis? Ankylosing spondylitis is a type of arthritis that causes inflammation in certain parts of the spine. Over time, this inflammation in the joints and tissues of the spine can cause stiffness. In severe cases, this may cause the bones in the spine to grow together, which can lead to a rigid spine that is difficult to bend. Many people with ankylosing spondylitis have mild episodes of back pain and stiffness that come and go. But others have severe, ongoing back pain and stiffness. Other symptoms also may develop if other areas of the body are affected
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.